CRSP

CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026. Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial Session Type: Late-Breaking Science (Oral Presentation) Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction Session Date and Time: Monday, November 9, 2026, 8:00 a.m.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and management's execution in ex vivo gene editing. Casgevy's Q2 sales grew 78% sequentially, reinforcing its blockbuster potential despite market skepticism and slow initial uptake. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, but clinical impact appears distant.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs.

Even if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year. That being said, CRISPR Therapeutics' developmental pipeline shows promise well beyond Casgevy's potential.